NCCN Guidelines for Patients® | Non-Small Cell Lung Cancer - page 73

73
NCCN Guidelines for Patients
®
: Non-Small Cell Lung Cancer
Version 1.2014
Part 7: Treatment by cancer stage
Par t 1
Par t 2
Par t 3
Par t 4
Par t 5
Par t 6
Par t 7
Par t 8
Par t 9
Notes:
!
Read pages 38–39
for information on
molecuar testing of
EGFR and ALK.
Research found that adding cetuximab to cisplatin and vinorelbine slightly
improved cancer treatment. This regimen can be used for any histologic
subtype. Bevacizumab can be used with platinum-doublet chemotherapy, such
as carboplatin and paclitaxel, for non-squamous lung cancers. To receive this
treatment, you should not have a recent history of coughing up blood (hemoptysis).
After two cycles of chemotherapy, the cancer’s response to treatment will be
tested. If there’s no cancer growth, a total of 4 to 6 chemotherapy cycles are
recommended. Afterward, the treatment response will be tested again. If the
cancer grows during first-line treatment, read
Treatments after first line
on page 76.
Otherwise, read
Maintenance therapy
on page 75.
_____________________
_____________________
_____________________
_____________________
_____________________
_____________________
_____________________
_____________________
_____________________
_____________________
_____________________
_____________________
_____________________
_____________________
_____________________
1...,63,64,65,66,67,68,69,70,71,72 74,75,76,77,78,79,80,81,82,83,...108
Powered by FlippingBook